Literature DB >> 20001516

Adiponectin and leptin levels in Chinese patients with HIV-related lipodystrophy: a 30-month prospective study.

Ling Luo1, Lu Zhang, Meimei Tao, Zhifeng Qiu, Jing Xie, Yang Han, Ming Li, Taisheng Li.   

Abstract

The relationship of adipocytokine with the development of HIV-related lipodystrophy was investigated in a case-control study. Adipocytokine, lipid, and glycemic parameters were measured at every visit. Logistic regression analysis was used to assess the HIV-LD risk factors and the Spearman correlation coefficients test was used to assess the correlation between adiponectin with other metabolic variables. Most of the patients (96.3%) developed HIV-LD after month 12. Comparing the baseline adiponectin, the adiponectin concentration of the HIV-LD group rose by month 6 and began to decrease substantially by month 18; this reduction was maintained until month 30 (p < 0.05). Comparing the HIV-NLD group, the adiponectin concentration at months 18, 24, and 30 were significantly lower in the HIV-LD group. The leptin concentration of both the HIV-LD and HIV-NLD groups remained stable. Patients in the lower concentration of baseline adiponectin and greater adiponectin change rate at month 18 presented with increased odds ratio for HIV-LD. The adiponectin level had a correlation with serum triglycerides (r = -0.616, p < 0.0001), serum insulin concentration (r = -0.494, p = 0.001), and HDL-C (r = 0.673, p < 0.0001). The adiponectin concentration of HIV-LD began to decrease substantially by month 18. The lower baseline concentration of adiponectin and the greater change rate at month 18 were independent risk factors of HIV-LD. The adiponectin level had a correlation with serum triglycerides, serum insulin concentration, and HDL-C, suggesting that adiponectin may link the metabolic abnormalities and HIV-LD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20001516     DOI: 10.1089/aid.2009.0072

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  FUNCTIONAL LIMITATIONS AND ADIPOKINES IN HIV-INFECTED OLDER ADULTS.

Authors:  K N Shah; Z Majeed; H Yang; J J Guido; T N Hilton; O Polesskaya; W J Hall; A E Luque
Journal:  J Frailty Aging       Date:  2015

2.  Bone and fat hormonal crosstalk with antiretroviral initiation.

Authors:  Arnold Z Olali; Qiuhu Shi; Donald R Hoover; Mariana Bucovsky; Elizabeth Shane; Michael T Yin; Ryan D Ross
Journal:  Bone       Date:  2021-09-20       Impact factor: 4.626

Review 3.  The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines.

Authors:  John Palios; Nikolaos P E Kadoglou; Stylianos Lampropoulos
Journal:  Exp Diabetes Res       Date:  2011-12-08

4.  Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy.

Authors:  Todd Hulgan; Benjamin S Ramsey; John R Koethe; David C Samuels; Mariana Gerschenson; Daniel E Libutti; Paul E Sax; Eric S Daar; Grace A McComsey; Todd T Brown
Journal:  J Acquir Immune Defic Syndr       Date:  2019-03-01       Impact factor: 3.771

Review 5.  HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings.

Authors:  Julia L Finkelstein; Pooja Gala; Rosemary Rochford; Marshall J Glesby; Saurabh Mehta
Journal:  J Int AIDS Soc       Date:  2015-01-15       Impact factor: 5.396

Review 6.  Multidisciplinary collaborative integrated management of increasingly prominent HIV complications in the post-cART era.

Authors:  L Lin; T S Li
Journal:  HIV Med       Date:  2020-12       Impact factor: 3.180

7.  Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy.

Authors:  Obiageli Offor; Netanya Utay; David Reynoso; Anoma Somasunderam; Judith Currier; Jordan Lake
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.